# Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of SKI2670

> **NCT02202408** · PHASE1 · COMPLETED · sponsor: **SK Chemicals Co., Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** SKI2670
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02202408
- **Lead sponsor:** SK Chemicals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02202408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02202408, "Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of SKI2670". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02202408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*